from Q1 2014 to Q3 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: ELITE PHARMACEUTICALS INC /NV/ quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q1 2014 to Q3 2023.
ELITE PHARMACEUTICALS INC /NV/ Deferred Tax Assets, Valuation Allowance for the quarter ending 30 Sep 2023 was $2,044,144.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2023	$2,044,144			30 Sep 2023	10-Q	14 Nov 2023	2024	Q2
Q1 2023	$20,434,000			31 Mar 2023	10-K	01 Jul 2024	2024	FY
Q1 2018	$19,213,000	-$10,702,000	-36%	31 Mar 2018	10-K	14 Jun 2018	2018	FY
Q1 2017	$29,915,000	+$2,882,000	+11%	31 Mar 2017	10-K	14 Jun 2018	2018	FY
Q1 2016	$27,033,000	+$27,008,453		31 Mar 2016	10-K	14 Jun 2018	2018	FY
Q1 2015	$24,547^*	-$19,788,453		31 Mar 2015	10-K	14 Jun 2017	2017	FY
Q1 2014	$19,813,000			31 Mar 2014	10-K	15 Jun 2016	2016	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.